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The interaction of factor Xa with factor Va on membranes to
form prothrombinase profoundly increases the rate of the pro-
teolytic conversionof prothrombin to thrombin.Wepresent the
characterization of an RNA aptamer (RNA11F7t) selected from a
combinatorial library based on its ability to bind factor Xa. We
show that RNA11F7t inhibits thrombin formation catalyzed by
prothrombinase without obscuring the active site of Xa within
the enzyme complex. Selective inhibition of protein substrate
cleavage arises from the ability of the aptamer to bind to factor
Xa and exclude interactions between the proteinase and cofac-
tor within prothrombinase. Competition for enzyme complex
assembly results from the binding of RNA11F7t to factor Xa with
nanomolar affinity in a Ca2-dependent interaction. RNA11F7t
binds equivalently to the zymogen factor X as well as derivatives
lacking -carboxyglutamic acid residues. We suggest that the
ability of RNA11F7t to compete for the Xa-Va interaction with
surprisingly high affinity likely reflects a significant contribu-
tion from its ability to indirectly impact regions of Xa that par-
ticipate in the proteinase-cofactor interaction. Thus, despite the
complexity of the macromolecular interactions that underlie
the assembly of prothrombinase, efficient inhibition of enzyme
complex assembly and thrombin formation can be achieved by
tight binding ligands that target factor Xa in a discrete manner.
The assembly of the prothrombinase complex is essential for
rapid thrombin formation after the initiation of blood coagula-
tion (1, 2). This macromolecular complex assembles though
reversible interactions between the serine proteinase, factorXa,
and its cofactor, factor Va, on membranes exposing amino-
phospholipids (1, 2). Although factor Xa itself can catalyze the
conversion of prothrombin to thrombin, its assembly into pro-
thrombinase yields a profound increase in catalytic efficiency
for thrombin formation (1, 2). Comparable interactions of
coagulation serine proteinases with their corresponding cofac-
tor onmembranes render equally spectacular enhancements in
function in other proteolytic activation steps of blood coagula-
tion (2, 3). Thus, membrane-dependent complex assembly and
its targeted down-regulation represent endogenous strategies
employed to achieve stringent biological control of product for-
mation in the individual steps of the clotting cascade (2).
Because dysregulated blood coagulation leading to excessive
clot formation is a principal contributor to human vascular dis-
ease and mortality, extensive efforts continue to be devoted
toward developing specific inhibitors for the modulation of
coagulation (4, 5). The conversion of prothrombin to thrombin,
the only activation step that is not duplicated in the pathway
toward thrombin formation, poses advantages as a potential
target for inhibition. This assertion has been borne out by the
success of inhibitors that target factor Xa for therapeutic gain
(4, 5). However, the widely practiced approach of developing
reversible inhibitors targeting the active site of factor Xa yields
ligands with unexpected inhibitory properties with respect to
the action of prothrombinase on its protein substrate (6, 7).
This arises in part from the major role played by extended sur-
faces, distinct from the active site, in driving the affinity of the
enzyme complex for prothrombin (7). In addition, reversible
inhibition of factor Xa interferes with endogenousmechanisms
of regulation including proteinase elimination by inhibitors
such as antithrombin III (8).
As the incorporation of factor Xa into prothrombinase yields
an105-fold increase in thrombin formation, disruption of the
high affinitymembrane-dependent interaction between factors
Xa and Va is expected to yield a dramatic reduction in the rate
of prothrombin activation. Accordingly, an inactive derivative
of factor Xa that competes with active Xa for interactions
within prothrombinase has proved an efficient inhibitor of clot
formation (9). Furthermore, because the assembly of pro-
thrombinase is largely unaffected by ligand binding to the active
site of the proteinase, disruption of prothrombinase can be
accomplished without abrogating active site function that is
otherwise also required for the down-regulation of proteinase
function by endogenous inhibitors (1, 2).
However, the membrane-dependent interaction between
factors Xa and Va is stabilized by linked protein-protein and
protein-membrane interactions within the complex (10). The
protein-protein contacts are most likely spread over multiple
sites as well as communicating domains in the interacting spe-
cies (11–13). These constraints coupledwith the likelihood that
some of these contacts occur over shallow surfaces point to
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difficulties in achieving high affinity inhibition of prothrombi-
nase assembly by small ligands that discretely target the inter-
acting species in a site-specific manner. This suggestion is con-
sistent with a long history documenting relatively inefficient
inhibition of prothrombinase function by peptides correspond-
ing to epitopes within Xa and Va considered responsible for
mediating their interactions within prothrombinase (13–16).
The systematic evolution of ligands by exponential enrich-
ment (SELEX)3 approach has proved useful for the develop-
ment of unique nucleic acid probes and/or inhibitors that bind
their target proteins with high affinity and specificity (17, 18).
We present the characterization of an RNA aptamer (RNA11f7t)
developed by cyclical screening of a combinatorial library
against factor Xa. We show that potent inhibition of thrombin
formation catalyzed by prothrombinase unexpectedly results
from the ability of RNA11f7t to bind factor Xa with high affinity
and inhibit its interaction with factor Va on the membrane
surface.
EXPERIMENTAL PROCEDURES
Reagents—Small unilamellar phospholipid vesicles (PCPS)
composed of 75% (w/w) hen egg L--phosphatidylcholine and
25% (w/w) porcine brain L--phosphatidylserine (Avanti Polar
lipids) were prepared and quality-controlled as described (19).
Peptidyl substrates methoxycarbonyl-D-cyclohexylglycyl-
glycyl-L-arginine-p-nitroanilide (SpXa) and H-D-phenylala-
nyl-L-pipecolyl-L-arginine-p-nitroanilide (S2238) were from
American Diagnostica and Chromogenix, respectively. Stock
solutions (4 mM) were prepared in water, and concentrations
were determined using E342  8270 M1cm1 (20). Oregon
Green488 maleimide, succinimidyl acetothioacetate (Invitro-
gen), L-glutamyl-L-glycinyl-L-arginine chloromethyl ketone
(EGR-CH2Cl, Calbiochem), chymotrypsin (Worthington), soy
bean trypsin inhibitor-Sepharose (Sigma), and (4-amidinophe-
nyl)-methanesulfonyl fluoride (APMSF, Sigma) were obtained
from the indicated suppliers. Acetothioacetyl-EGR-CH2Cl was
prepared, purified, and characterized as described (21). Human
plasma used for protein isolation was a generous gift of the
Plasmapheresis unit of the Hospital of the University of Penn-
sylvania. Unless otherwise specified, fluorescence and activity
measurements were performed in 20mMHepes, 150mMNaCl,
5 mM CaCl2, 0.1% (w/v) polyethylene glycol 8000, pH 7.5 (assay
buffer) at 25 °C.
Proteins—Factor X, prothrombin, antithrombin III, factor
IX, and factor V were isolated from human plasma using estab-
lished procedures (22–24). Human factor X was freed of trace
contaminants by chromatography on soy bean trypsin inhibi-
tor-Sepharose and immunoaffinity chromatography using the
Ca2-dependent monoclonal antibody 4G3 (21, 25). Factor X
and traces of Xa were depleted from the prothrombin and fac-
tor IX preparations using the same approach. Prethrombin 2
and thrombin were obtained by preparative proteolysis of pro-
thrombin followed by isolation as detailed (26). Factors Xa and
Va were prepared by proteolytic activation of factors X and V,
respectively, and repurification as before (21). Factor Xa prep-
arations contained approximately equimolar amounts of the 
and  forms and yielded 1.1–1.2 mol of active sites/mol of pro-
tein in kinetic titrations with p-nitrophenol p-guanidinoben-
zoate (27). Quality control of the factor Va preparations was
performed by equilibrium binding measurements of the ability
of factor Va to assemble into prothrombinase (below). Factor
Xa was inactivated with APMSF and purified to yield Xai or
inactivated with acetothioacetyl-EGR-CH2Cl, reacted with
Oregon Green488 maleimide after thioester hydrolysis, and
purified to yield OG488-Xa (21). A derivative of factor Xa lack-
ing the -carboxyglutamate domain was prepared by proteoly-
sis using chymotrypsin pretreated with tosyl-lysine chloro-
methyl ketone andpurified as described (28, 29). The productwas
inactivatedwithAPMSF to yieldGla-Xai. Recombinant factor
X containing an Ala substitution for the catalytic serine
(XS195A)was expressed inHEK293 cells and purified to separate
fully -carboxylated species from the uncarboxylated species as
before (30). The fraction devoid of -carboxyglutamic acid
(desGla-XS195A) was activated and purified by affinity chroma-
tography with soy bean trypsin inhibitor-Sepharose to yield
desGla-XaS195A (30). Described procedures were used to con-
vert IX to IXa and repurify the product (24). Recombinant
factor VIIa was fromNovo-Nordisk (Denmark) and full-length
recombinant factor VIII was obtained as a generous gift from
Lisa Regan (Bayer, Berkeley, CA). Recombinant tissue factor
(TF) was reconstituted into PCPS vesicles and quality con-
trolled as described (31). Recombinant factor VIII was repuri-
fied by anion exchange chromatography as described (32), dia-
lyzed into assay buffer supplemented with 0.02% (v/v) Tween
20, and stored at80 °C. A recombinant version of tissue factor
pathway inhibitor comprising residues 13–161 (TFPI13–161)
was produced in HEK293 cells and purified from conditioned
medium. Protein concentrations were determined using the
following molecular weights (Mr) and extinction coefficients
(E280, mg1cm2): prothrombin, 72,000, 1.47 (26); prethrombin
2 and thrombin, 37,500, 1.89 (26); X, 56,500, 1.16 (33); Xa, Xai,
XaS195A and desGla-XaS195A, 45,300, 1.16 (33); Gla-Xai,
38,000, 1.16; Va, 168,000, 1.74 (21, 34); IXa, 46,000, 1.32 (35);
VIIa, 50,000, 1.39 (36); VIII, 264,700, 1.22 (37); TFPI13–161,
17,400, 0.45 calculated from the primary sequence by the
method of Gill and von Hippel (38).
Generation of RNA Aptamers—SELEX procedures were
carried out as previously described (39–41). The sequence of
the starting RNA combinatorial template was 5-GGGAGAG-
AGGAAGAGGGATGGGN40CATAACCCAGAGGTCGAT-
AGTACTGGATCCCCCC-3, where N40 represents 40 nucle-
otides containing equimolar A, G, C, and U residues at each
position. The 2-fluoro derivatives of cytidine triphosphate and
3 The abbreviations used are: SELEX, systematic evolution of ligands by expo-
nential enrichment; APTT, activated partial thromboplastin time; APMSF,
(4-amidinophenyl)-methanesulfonyl fluoride; desGlaXaS195A, recombinant
human factor Xa with the catalytic serine substituted with alanine and
lacking -carboxyglutamic acid modifications; Gla-Xai, Xai lacking resi-
dues 1– 44 comprising the -carboxyglutamic acid-containing domain;
EGR-CH2Cl, L-glutamyl-glycinyl-L-arginine chloromethyl ketone; OG488-Xa,
Xa inactivated with acetothioacetyl-EGR-CH2Cl and reacted with Oregon
Green488 maleimide; PCPS, small unilamellar phospholipid vesicles con-
taining 75% (w/w) hen egg L--phosphatidylcholine and 25% (w/w)
porcine brain L--phosphatidylserine; PT, prothrombin time; S2238, H-D-
phenylalanyl-L-pipecolyl-L-arginine-p-nitroanilide; SpXa, methoxycarbon-
yl-D-cyclohexylglycyl-glycyl-L-arginine-p-nitroanilide; TFPI13–161, recombi-
nant truncated tissue factor pathway inhibitor comprising residues
13–161; APMSF, (4-amidinophenyl)-methanesulfonyl fluoride; Xai, Xa inac-
tivated with APMSF; TF, tissue factor.
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uridine triphosphate (TriLink Biotechnologies) were incorpo-
rated into RNA libraries by in vitro transcription as described
(40). In vitro selectionwas performedby incubation of 5 nmol of
RNA with 0.5 nmol of Xa in 20 mM Hepes, 0.05 M NaCl, 2 mM
CaCl2, 0.01% (w/v) bovine serum albumin, pH 7.4, followed by
isolation of proteinase-bound RNA by filtration through a
0.45-m nitrocellulose membrane (Schleicher and Schuell).
Bound RNA was eluted using phenol:chloroform:isoamyl alco-
hol (25:24:1) and precipitated with ethanol. One-quarter of the
precipitated RNA was amplified by reverse transcriptase PCR.
The product was transcribed, and the resulting RNA was used
in the next round of selection. As the rounds progressed, the
concentration of Xa was decreased to increase the ratio of RNA
to protein. After 11 rounds of selection, the products were
digested with EcoR1 and BamH1 (New England Biolabs) and
directionally cloned into pUC19 linearized with the same
enzymes. Individual clones were sequenced, and clonal RNA
transcripts were analyzed in filter binding assays. The lead
molecule was systematically shortened to obtain a truncated
version (RNA11F7t) that retained binding activity. In parallel
studies point mutations were introduced to yield RNAMUT
with a greatly reduced ability to bind Xa. Ribooligonucleoti-
des were chemically synthesized by Dharmacon Research
and supplied desalted after deprotection form 2-hydroxy-
lated purines. The aptamer RNA11F7t corresponded to 5-
GAGAG(2FC)(2FC)(2FC)(2FC)AG(2FC)GA GA(2FU)A-
A(2FU)A(2FC)(2FU)(2FU)GG(2FC) (2FC)(2FC)(2FC)G-
(2FC)(2FU)(2FC)(2FU) (2FU)-idT, and RNAMUT comprised
5-GAGAG(2FC)(2FC)(2FC)(2FC)AG(2FC)GAGA(2FU)-
AA(2FU)A(2FC)(2FU)(2FU)G(2FU)A(2FC)(2FC)(2FC)G-
(2FC)(2FU)(2FC)(2FU)(2FU)-idT, where 2FC is 2-flu-
rocytosine, 2FU is 2flurouracil, and idT denotes inverted
deoxythymidine. RNAMUT differs from RNA11F7t by substi-
tutions at positions 26 and 27. Aptamers were dissolved in
assay buffer or dialyzed into assay buffer lacking polyethyl-
ene glycol and stored at 20 °C. Concentrations were deter-
mined using E260  353,000 M1cm1. The calculated for-
mula weight (11,827) was confirmed by mass spectrometry
performed at the Emory University Microchemical Facility.
Aptamer preparations were renatured before each use by
melting at 60 °C for 5 min followed by cooling to ambient
temperature.
Coagulation Measurements—Clotting assays were per-
formed using amodel ST4mechanical coagulometer (Diagnos-
tica Stago). For measurements of the prothrombin time (PT),
50 l of pooled normal human plasma (George King Bio-Med-
ical) was incubated for 5 min at 37 °C with increasing concen-
trations of aptamer. Clotting was initiated by the addition of
100l of Simplastin (BioMerieux). For activated partial throm-
boplastin time (APTT) measurements, 50 l of pooled normal
human plasma was mixed with 50 l of MDA platelin reagent
(BioMerieux) and incubated with increasing concentrations of
aptamer for 5 min at 37 °C. Clotting was initiated by the addi-
tion of 50 l of 25 mM CaCl2. Clotting results are presented as
the ratio of clot times in the presence of aptamer to the clot time
in buffer.
Protein/RNA Binding—Binding measurements were con-
ducted with 32P end-labeled RNA using purified coagulation
proteins obtained from Hematologic Technologies as previ-
ously detailed (39). Proteins were serially diluted in 20 mM
Hepes, 150 mM NaCl, 2 mM CaCl2, 0.01% (w/v) bovine serum
albumin containing a fixed and trace amount of end-labeled
RNA. After incubation at 37 °C, reactionmixtures were filtered
under vacuum with a Protran membrane (Schleicher and
Schuell) positioned over a GeneScreen Plus nylon membrane
(PerkinElmer Life Sciences) to adsorb protein-bound RNA
and free RNA, respectively. Binding constants were esti-
mated as previously described (39, 40).
Progress Curves for Prothrombin Cleavage—Reaction mix-
tures (300 l) containing 1.4 M prothrombin, 36 M PCPS, 30
nM Va with or without 250 nM RNA11F7t or RNAmut at 25 °C
were initiated with 0.2 nM Xa. Aliquots (10 l), withdrawn at
various times after initiation, were quenched bymixing with 90
l of assay buffer lacking Ca2 but containing 50 mM EDTA.
Quenched samples were further diluted in the same buffer in
wells of a 96-well plate, and initial rates of S2238 hydrolysis
were determined by monitoring the change in absorbance at
405 nm after the addition of 100 M peptidyl substrate using a
Gemini kinetic plate reader (Molecular Devices). Initial rates
were converted to concentrations of proteinase product(s)
formed as a function of time from the linear dependence of
initial rate on known concentrations of thrombin.
Initial Velocity Studies of Prethrombin 2 Cleavage—Initial
velocity measurements of thrombin formation from prethrom-
bin 2 were determined discontinuously using the strategy de-
scribed above with the detailed considerations previously
described (6). Trivial effects on initial rates were ruled out by
the equivalence in rates of S2238 hydrolysis catalyzed by
thrombin both in the absence or presence of the highest con-
centrations of aptamer used. In each case initial velocities were
determined from the linear appearance of product with time in
six serially quenched samples. For studies of the inhibition
of prethrombin 2 cleavage by increasing concentrations of
aptamer, reaction mixtures contained either 1.4 or 3.0 M pre-
thrombin 2, 50 M PCPS, 40 nM Va, the indicated concentra-
tions of aptamer and 5 nM Xa. Equivalent results were obtained
when reactions were initiated with Xa or with prethrombin 2
after prolonged incubation of aptamer with the Xa/Va/PCPS
mixture. For studies in which the concentration of factor Va
was varied, reactionmixtures contained 1.4 M prethrombin 2,
50 M PCPS, the indicated concentrations of Va, 5 nM Xa, and
aptamer concentrations fixed at 0, 0.05, 0.2, 1.0, and 2.0 M.
Peptidyl Substrate Hydrolysis by Xa and Prothrombinase—
Reaction mixtures (150 l) containing 1 nM Xa or 1 nM Xa plus
50 M PCPS with Va fixed at 0, 5, 15, and 50 nM and increasing
concentrations of the indicated aptamer were initiated with
SpXa (50 l) to achieve a final concentration of 100 M. Initial
velocitieswere determined in a kinetic plate reader. Steady state
constants were determined by initial velocity measurements
either in the absence or presence of 250 nMRNA11F7t by varying
the concentration of SpXa to 240 M (24 values) using either 1
nM Xa, 1 nM Xa plus 60 M PCPS or 1 nM Xa, 60 M PCPS and
15 nM Va.
FluorescenceMeasurements—All steady state fluorescence
measurements were performed at 25 °C using a PTI
QuantaMaster fluorescence spectrophotometer (Photon
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Technology Inc.). Intensity measurements of the binding of
aptamer to OG488-Xa were performed in assay buffer supple-
mentedwith 0.02% (v/v) Tween 20,which prevented systematic
and time-dependent decreases in fluorescence at low concen-
trations of aptamer, possibly because of adsorption artifacts.
Ratiometric fluorescence intensity was recorded by averaging
30 readings over 30 s using EX  490 nm and EM  520 nm
with a KV-500 (Schott Glass) long pass filter in the emission
beam and polarizers oriented under “Magic Angle” conditions
(42). Reaction mixtures (2.5 ml) in 1  1-cm stirred cuvettes
typically contained 15–18 nM OG488-Xa, and intensity was
recorded after matched incremental additions of RNA11F7t,
RNAMUT, or buffer. For measurements in the absence of Ca2,
the buffer contained 50 M EDTA in the place of 5 mM Ca2.
Division of the signal observed in samples containing
aptamer by the signal of the buffer sample yielded the nor-
malized change in fluorescence in OG488-Xa, corrected for
dilution (F/Fo). For competitive binding measurements,
reaction mixtures contained 18 nM OG488-Xa and different
fixed concentrations (between 15 and 80 nM) of RNA11F7t
matched with a sample containing the same concentration of
RNAMUT. Fluorescence intensity was recorded after equal
incremental additions of competitor to both cuvettes. F/Fo
was calculated by dividing the signal observed in the sample
containing RNA11F7t by that observed in the sample contain-
ing RNAMUT.
Fluorescence anisotropy measurements of the membrane-
dependent interaction of OG488-Xa with factor Va were per-
formed as previously detailed (21). For competition studies
with aptamer, reaction mixtures (2.5 ml) in assay buffer con-
tained 35 nM OG488-Xa, 50 M PCPS, and fixed aptamer con-
centrations of 0, 0.35, 2, and 5M. Fluorescence anisotropy and
total intensity were measured after incremental additions of
factor Va as previously described (21). All measurements were
corrected for scattering using a parallel reaction mixture con-
taining 35 nM Xai in place of OG488-Xa. Small decreases in the
anisotropy of OG488-Xa in the presence of aptamer were
accommodated by expressing the data as the change in anisot-
ropy (r) from the sample lacking Va.
Sedimentation Equilibrium—Analytical ultracentrifugation
was performed using an AN60-Ti rotor in a XL-I instrument
(Beckman Coulter). Samples were dialyzed extensively into 20
mMHepes, 0.15MNaCl, 5mMCa2, pH7.4, and 100-l aliquots
were loaded into 6 sector cells with an epon centerpiece and
sapphirewindows. Centrifugationwas at 20 °C using increasing
rotor speeds of 15,000, 20,000, 25,000, and 30,000 rpm. Absor-
bance scans were collected at 260 and 280 nm between 20 and
22 h after the rotor had achieved speed, and an equilibrium
distribution of species was verified by the equivalence of suc-
cessive scans obtained after an additional 4 or 8 h had elapsed.
Right Angle Light Scattering—Measurements were per-
formed in the fluorescence spectrophotometer at 25 C using
EX  EM  320 nm. Reaction mixtures (2.5 ml) contained
assay buffer alone, 0.3 M Xai, 0.6 M RNA11F7t, or 0.3 M Xai
plus 0.6 M RNA11F7t. Scattering intensity was measured by
averaging readings for 30 s after incremental additions of PCPS
(0–30 M) to all four cells. Scattering changes associated with
membrane binding were determined by subtracting the linear
dependence of scattering intensity from the sample lacking Xai
from the experimental sample.
Inhibition of Factor Xa by Macromolecular Inhibitors—The
first order decay in Xa (10 nM) in the presence of antithrombin
III (2.0 M) was measured in assay buffer at 25 °C either in the
absence or presence of 270 nM RNA11F7t using approaches pre-
viously described (24). Inhibition studies with TFPI13–161 were
performed after prolonged incubation of proteinasewith inhib-
itor as previously detailed (43). For thesemeasurements, 0.4 nM
Xa was incubated with increasing concentrations of TFPI13–161
(0–4 nM, 24 concentrations) either without or with 254 nM
RNA11F7t for 1 h at room temperature before residual Xa activ-
ity was determined with SpXa.
Kinetics of Factor XActivation—Initial velocity studies of fac-
tor X activation by VIIa.TF were conducted using described
procedures (31). Xa formation was determined using 100 nM
factor X ([S]  Km), 0.1 nM VIIa, and 43 nM TF incorporated
into PCPSmembranes (43 nMTF, 50MPCPS) with increasing
concentrations of RNA11F7t. A similar strategywas employed in
studies of Xa formation by IXaVIIIa. Factor VIII (40 nM), rap-
idly activated by a 30-s incubation with 3 nM thrombin, was
treated with 40 nM hirudin and further diluted to prepare a 2
enzyme solution containing 0.4 nM IXa, 100 M PCPS, and 20
nM VIIIa. Xa formation was initiated by mixing with an equal
volume of 80 nM factor X containing increasing concentrations
of RNA11F7t followed by discontinuousmeasurements of initial
velocity. Measured steady state kinetic constants for Xa forma-
tion in the absence of aptamer under these conditions were
Km  33.8  1.4 nM and V/E  1.65  0.08 s1.
Activation of VIII—Factor VIII activation was initiated by
the addition of 3 nM proteinase (thrombin or Xa) to reaction
mixtures containing 30 M PCPS and 50 nMVIII in assay buffer
plus 0.02% Tween 20 with and without 256 nM RNA11F7t.
Aliquots were removed at the indicated times and quenched by
mixingwith an equal volume of 125mMTris, 50mMEDTA, 120
mM dithiothreitol, 2% (w/v) SDS, 20% (v/v) glycerol, 0.02%
(w/v) bromphenol blue, pH 6.8, heated at 90 °C, and subject
to SDS-PAGE. Products were detected by Western blotting
as previously detailed (22), using a monoclonal antibody
directed toward the A2 domain (GMA-012, GreenMountain
Antibodies).
Data Analysis—Data were analyzed according to the indi-
cated equations by nonlinear least squares regression employ-
ing the Levenberg-Marquardt algorithm (44). Fitted parame-
ters are listed 95% confidence limits. The data illustrated are
typically representative of two or more experiments performed
at a similar level of detail. In some instances we have employed
normalization approaches to permit the simultaneous display
and analysis of multiple experiments performed with different
preparations of the interacting species.
The change in OG488-Xa fluorescence with increasing con-
centrations of aptamer was analyzed assuming the interaction
of the varied ligand with equivalent and non-interacting sites
using Equation 2 in Betz and Krishnaswamy (45) to yield fitted
values for Kd, mol of aptamer bound/mol of OG488-Xa at satu-
ration, and the limits of the fluorescence change (Fo and Fmax/
Fo). Competitive bindingmeasurementswere analyzedwith the
same assumptions employing the Newton-Raphson solution of
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cubic Equation 17 in Olson et al. (46) to yield fitted values for
Kd and stoichiometry for the binding of RNA11F7t to
OG488-Xa and its binding to the competing species, Fmax/Fo
for the indicator reaction and F/Fo at infinite concentrations
of competitor. Because of high parameter correlation, anal-
ysis of some data sets was done by fixing the stoichiometry
for the binding of RNA11F7t to OG488-Xa to 2 and/or F/Fo at
infinite competitor to 1.
Absorbance as a function of radial position acquired at two
wavelengths and multiple speeds at sedimentation equilibrium
were globally analyzed using SEDPHAT (47). Calculationswere
constrained by mass conservation, and the molecular weight
was derived using   1.0046 g/cm3 and v  0.508 cm3/g (48).
Confidence limits (67%) of the fits were calculated by Monte-
Carlo analysis.
Activity and anisotropy measurements examining pro-
thrombinase assembly in the absence or presence of fixed con-
centrations of aptamer were performed at saturating concen-
trations of PCPS, which allows for the determination of
equilibrium binding parameters for the membrane-dependent
interaction between Xa and Va as previously detailed (10). The
dependence of the initial rate of thrombin formation on
increasing concentrations of factor Va at different fixed con-
centrations of aptamer were analyzed by assuming mutually
exclusive binding interactions in rapid equilibrium between Xa
and factor Va versusXa and aptamer. Analysis according to the
cubic equation of reference (46) yielded fitted values for Kd for
the membrane-dependent interaction between Xa and Va
(KdXa,Va), mol of Va bound/mol of Xa at saturation, Kd for
aptamer binding to Xa (KdRNA, Xa), mol of aptamer bound/mol
of Xa at saturation, rate at zero Va, and rate at infinite Va.
Anisotropy measurements of the binding of increasing con-
centrations of Va toOG488-Xa in the presence of different fixed
concentrations of aptamer were analyzed with the same
assumptions and an equivalent strategy. To accommodate bias
introduced by differential increases in fluorescence intensity
that accompany the binding of OG488-Xa to Va (Fmax/Fo 
1.38) or to aptamer (Fmax/Fo  1.76), the observed change in
anisotropy at any given concentration of Va (robs) was related
to the fractional saturation of OG488-Xa with Va (fb) by the
expression analogous to that described by Lakowicz (42),
robs 
Rrmaxfb
1  fb	R 	 1

(Eq. 1)
wherermax is themaximumchange in anisotropy at saturating
Va, and R is the ratio of intensities for OG488-Xa saturated with
Va and OG488-Xa in the absence of Va. In the presence of fixed
concentrations of aptamer, the intensity of OG488-Xa uncom-
plexed with Va was higher than that at saturating Va. Analysis
by these approaches yielded fitted values for Kd for the membrane-
dependent interaction between OG488-Xa and Va (KdXa,Va),
mol of Va bound/mol of OG488-Xa at saturation, Kd for
aptamer binding to OG488-Xa (KdRNA,Xa), mol of aptamer
bound/mol of OG488-Xa at saturation, and the maximum
change in anisotropy (rmax) at infinite Va.
RESULTS
Specificity of RNABinding—Screens for binding specificity of
RNA11F7t using filter binding assays revealed the ability of the
aptamer to discriminate between the homologous proteinases
of coagulation (Table 1). Binding with apparently nanomolar
affinity was observed with factor Xa, whereas the other coagu-
lation proteinases bound weakly
with Kd  3 M (Table 1). Thus,
RNA11F7t exhibits 2700-fold se-
lectivity for binding to Xa over the
other coagulation proteinases.
Inhibition of Biological Function—
RNA11F7t was an effective inhibi-
tor of clot formation in human
plasma. Increasing concentrations of
RNA11F7t prolonged both the PT as
well as theAPTT (Fig. 1A). It follows
that the binding of RNA11F7t inhib-
its some or all functions of factor
Xa that regulate clot formation in
plasma. Specificity for inhibition
is documented by the lack of effect
of RNAMUT on the clotting time in
either assay format (Fig. 1A). The
apparently larger impact of
RNA11F7t on the APTT relative to
the PT suggests potentially com-
FIGURE 1. Aptamer-dependent inhibition of biological function. Panel A, shown is plasma clotting. The
effects of increasing concentrations of RNA11F7t (F, E) or RNAMUT (Œ, ‚) on the APTT (open symbols) or the PT
(closed symbols) of normal human plasma are illustrated. The dashed line denotes the increase in APTT seen
with factor X-deficient plasma compared with normal human plasma (solid line). Symbols and error bars denote
the mean  S.D. from three measurements. Panel B, shown is prothrombin activation by prothrombinase.
Progress curves for the formation of proteinase product were constructed using reaction mixtures containing
1.4 M prothrombin, 36 M PCPS, 30 nM Va, and 0.2 nM Xa with no addition (F), 250 nM RNAMUT (E), or 250 nM
RNA11F7t (Œ). Results with two independent preparations of RNA11F7t are illustrated. The lines were arbitrarily
drawn.
TABLE 1
Binding Specificity of RNA11F7t
Apparent binding affinities were determined by filter binding using trace concen-
trations of RNA11F7t, and increasing concentrations of the indicated proteinase.
Values of Kd  3 M denote instances in which binding of RNA11F7t to the protein
remained low and was not saturated at concentrations as high as 3 M.
Proteinase target Kd
nM  S.D.





Activated protein C 3000
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plex effects of the aptamer in these plasma assays. Further
insights into the ability of RNA11F7t to inhibit coagulation
were sought through studies in purified and reconstituted
systems. Progress curves for the activation of prothrombin,
present at its physiological concentration, by factor Xa satu-
rably incorporated into prothrombinase revealed that 250
nM RNA11F7t inhibited the initial rate of product formation
by 85%, whereas RNAMUT was without effect (Fig. 1B).
These findings establish RNA11F7t as an inhibitor of pro-
thrombinase and indicate that its ability to prolong clot time
is at least partly related to its ability to inhibit thrombin
formation. However, interpretations are compromised by
the fact that prothrombin is activated by two successive
cleavage reactions with two possible pathways for thrombin
formation (49). Because both thrombin and the intermediate
meizothrombin are detected as products in this measure-
ment, interpretation could be compromised by complex
effects of the aptamer on the enzyme as well as pathway for
product formation. Consequently, further characterization
of the inhibitory properties of RNA11F7t was pursued using
prethrombin 2 as a substrate analog. Prethrombin 2 is
cleaved by prothrombinase at a single site to yield thrombin
with kinetic constants that can be interpreted in the tradi-
tional way without the added complexities associated with
multiple enzyme-catalyzed reactions or rate-limiting effects
of membrane-mediated substrate delivery to the enzyme
(50). This reaction is established to mirror the features of the
first cleavage reaction in prothrombin activation by pro-
thrombinase (23).
Inhibition of Prethrombin 2Cleavage—Initial velocity studies
of prethrombin 2 activation catalyzed by Xa assembled into
prothrombinase with saturating concentrations of PCPS and
Va confirmed the initial findings with prothrombin (Fig. 2).
Increasing concentrations of RNA11F7t reduced the initial
velocity for thrombin formation, whereas no obvious decrease
in rate was observed with RNAMUT (Fig. 2). Because the two
aptamers differ in composition and sequence by only two
nucleotide bases, these findings again establish specificity in the
ability of RNA11F7t to inhibit prothrombinase function. It also
appears improbable that this inhibitory effect arises from the
polyanionic character of the aptamer or from some other
common feature of ribooligonucleotides in general. Inhibi-
tion by RNA11F7t was the same when reaction mixtures were
initiated with Xa or after prolonged incubation of aptamer
with preformed prothrombinase (Fig. 2). Thus, inhibition
proceeds rapidly compared with the time scale of steady
state initial velocity measurements. Furthermore, normal-
ized inhibition by RNA11F7t was not significantly affected by
doubling the concentration of prethrombin 2 (Fig. 2). As the
concentration of prethrombin 2 was well below the Km (51),
extent of inhibition normalized as V/Vo (Fig. 2) is expected
to be most sensitive to substrate concentration if inhibition
results from interference with substrate binding to pro-
thrombinase. Therefore, RNA11F7t is unlikely to compete for
substrate binding to prothrombinase.
Active Site Function—A hallmark of the unique strategy
employed in the recognition of the protein substrate by pro-
thrombinase is that although competitive inhibition requires
ligands that block exosite-dependent tethering of the substrate
to enzyme, those directed toward the active site of the catalyst
uniformly act as classical non-competitive inhibitors (7). The
latter possibility could readily explain the findings in Fig. 2.
Initial velocity studies of peptidyl substrate hydrolysis were
used to assess effects of RNA11F7t on active site function of
factor Xa in the absence or presence of the other constituents
of prothrombinase (Fig. 3). Increasing concentrations of
RNA11F7t had no obvious effect on the rate of peptidyl sub-
strate hydrolysis at Km concentrations of substrate when
the catalyst was Xa alone or Xa saturated with PCPS (Fig. 3).
In the absence of aptamer, initial rate was reduced by 50%
when both PCPS and Va were present (Fig. 3). This decrease
arises from the established 2-fold increase in Km for SpXa
FIGURE 2. Inhibition of prethrombin 2 activation. Initial velocities of throm-
bin formation were determined using increasing concentrations of RNA11F7t
(F, E) or RNAMUT (Œ) in reaction mixtures containing 50 M PCPS, 40 nM Va, 5
nM Xa, and either 1.4 M (F, Œ) or 3.0 M (E) prethrombin 2. The results of five
different experiments are presented after normalization as v/vo, where vo is
the initial rate observed in the absence of added RNA for each experiment.
FIGURE 3. Peptidyl substrate cleavage. Initial velocities for SpXa hydrolysis
were determined with increasing concentrations of RNA11F7t with 100 M
SpXa and 1 nM Xa (Œ), 1 nM Xa, plus 50 M PCPS (F) or 1 nM Xa, 50 M PCPS, plus
5 nM Va (E), plus 15 nM Va (‚), or plus 50 nM Va (ƒ). Initial rates with increasing
concentrations of RNAMUT () were determined using 1 nM Xa, 50 M PCPS,
and 50 nM Va. The lines were arbitrarily drawn.
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that accompanies the incorporation of factor Xa into pro-
thrombinase (21). Under these conditions, increasing con-
centrations of RNA11F7t restored the initial rate to that
observed in the absence of factor Va, whereas RNAMUT had
no such stimulatory effect (Fig. 3). The RNA11F7t-dependent
increase in rate varied with different fixed concentrations of
Va (Fig. 3). Steady state kinetic constants confirmed that the
modest increase in rate observed at 250 nM RNA11F7t
resulted from a correction of the larger Km (205  10 M)
observed in the presence of Va to a value (102  6 M) that
was indistinguishable from that observed with Xa alone
either in the presence or absence of PCPS. These results rule
out the possibility that RNA11F7t affects enzyme function by
blocking or restricting substrate access to the active site of
Xa or Xa within prothrombinase. The ability of RNA11F7t to
increase the rate in the presence of Va and PCPS and the
peculiar dependence of this rate-enhancing effect on the
fixed concentration of Va imply that the aptamer may inter-
fere with the interaction between Xa and Va. However,
definitive conclusions are precluded by the modest rate
effects.
Binding ofAptamer toXa—Fluorescencemeasurementswith
OG488-Xa revealed a large change in steady state intensity upon
the addition of RNA11F7t. Titration of OG488-Xa with increas-
ing concentrations of RNA11F7t yielded a saturable increase in
fluorescence with features of a tight binding interaction that
saturated at 2 eq of added RNA11F7t (Fig. 4). The titration
curve was obviously sigmoid when performed in assay buffer
with time-dependent decreases in intensity at low concentra-
tions of aptamer (not shown). These features were greatly
reduced when measurements were performed after precondi-
tioning the cuvette with 0.2% (v/v) Tween 20 or when assay
buffer contained 0.02% (v/v) Tween 20 (Fig. 4).We assume that
inclusion of detergent resolves artifacts related to protein
adsorption at low aptamer concentrations. However, we are
uncertain if this manipulation has deliberately obscured intrin-
sic positive cooperativity in the binding interaction. Analysis
assuming the interaction of RNA11F7t with equivalent and non-
interacting sites yielded a Kd  0.7 nM with 2 mol of aptamer
bound bound/mol of OG488-Xa at saturation (Fig. 4). No
change in fluorescence intensity was observed when the buffer
contained 50 M EDTA in place of 5 mM Ca2 or with increas-
ing concentrations of RNAMUT (Fig. 4). RNA11F7t binding
and/or the fluorescence change associated with the binding
interaction requires the presence of Ca2. The lack of fluores-
cence increase observed with increasing concentrations of
RNAMUT illustrates the specificity of the interaction inferred in
this way. Reversibility of the inferred interaction was docu-
mented by the ability of increasing concentrations of Xai to
effectively decrease fluorescence intensity of the preformed
aptamer-OG488-Xa complex to a value expected for OG488-Xa
in solution (Fig. 4, inset). Analysis of the competitive equilibria
yielded parameters for the interaction of RNA11F7t withXai that
were similar to those for its interaction with the fluorescent Xa
derivative (Table 2). Therefore, the inferred binding of aptamer
toOG488-Xa is not affected in an obviousway by the presence of
the bulky fluorophore or occlusion of the active site with the
peptidyl chloromethyl ketone. Protein specificity was estab-
lished by the inability of prothrombin to compete with
OG488-Xa for aptamer binding (Table 2). RNA11F7t was found
to bind equivalently to both X and Xa (Table 2), indicating the
inability of the aptamer to distinguish between the zymogen
FIGURE 4. Binding of RNA species to factor Xa. Steady state fluorescence
intensities were measured using reaction mixtures containing 18 nM
OG488-Xa titrated with increasing concentrations of RNA11F7t (F) or RNAMUT
(E) in assay buffer containing 0.02% (v/v) Tween 20. Titrations with RNA11F7t
were also performed in the same buffer lacking Ca2 but supplemented with
50 M EDTA (Œ). The line is drawn after analysis as described with the fitted
values: Kd  0.67  0.06 nM, n  2.13  0.02 mol of RNA11F7t/mol of OG488-Xa
at saturation, Fmax/Fo  1.76  0.01, and Fo  0.996  0.003. Inset, competi-
tive binding studies performed with 15 nM OG488-Xa and increasing concen-
trations of Xai in the presence of 20 nM (Œ), 40 nM (F), and 80 nM (E) RNA11F7t.
The lines are drawn after analysis according to competitive equilibria
using the fitted parameters listed in Table 2.
TABLE 2
Equilibrium constants for RNA11F7t binding determined by fluorescence competition
Binding parameters were determined from competition studies similar to those illustrated in Fig. 4 inset. Fitted parameters are listed 95% confidence limits.
Competitora
RNA11F7t/OG488-Xa interaction RNA11F7t/competitor
Kd Mol RNA/mol OG488-Xa Fmax/Fo Kd Mol RNA/Mol competitor
nM nM
Xai 1.26  0.23 1.96  0.04 1.76  0.01 0.61  0.10 2.08  0.04
Prothrombin NDb
X 0.79  0.13 2.0 (F)c 1.75  0.01 0.56  0.08 1.89  0.05
GlaXai 0.42  0.13 2.0 (F) 1.70  0.01 0.35  0.10 1.78  0.05
desGlaXaS195A 1.12  0.40 1.87  0.04 1.75  0.02 0.87  0.28 2.05  0.07
desGlaXS195A 1.56  0.36 2.09  0.05 1.78  0.01 0.85  0.19 1.88  0.04
a Fluorescence intensity was measured using increasing concentrations of the indicated competitor in the presence of OG488-Xa and two or three different fixed concentrations
of RNA11F7t.
b No competition detected.
c Terms used as constants in the analysis are indicated as F.
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and proteinase. Finally, despite the strong Ca2 dependence of
the binding of RNA1F7t toOG488-Xa, competitive binding stud-
ies with a proteolytic derivative of Xai lacking the -carboxy-
glutamic acid domain or recombinant derivatives of X and Xa
lacking posttranslational modification with -carboxyglutamic
revealed that affinity and stoichiometry for RNA11F7t binding
was independent of this region well known to participate in
Ca2 binding (Table 2).
Solution Molecular Weights—Analytical ultracentrifugation
was used to assess dimerization of the aptamer in solution,
which could provide an explanation for the stoichiometries
consistently observed in the binding measurements. Concen-
tration distributions of RNA11F7t at sedimentation equilibrium
could be adequately described by analysis according to a single
sedimenting species with a molecular weight of 12,604  109
(Fig. 5). Agreement with the formula weight of 11,827 suggests
that the aptamer is predominantly monomeric even at M con-
centrations. Although the modest discrepancy could reflect
counterions bound to the oligonucleotide, uncertainty in v
most likely also contributes to this difference. Further analysis
assuming a monomer-dimer equilibrium produced a small
improvement in the fit (not shown), providing a lower limit
estimate of 20 M for the equilibrium dissociation constant for
dimer formation. Thus, negligible concentrations of dimeric
aptamer are expected to preexist at the concentrations used
throughout this study. Additional efforts sought to indepen-
dently establish the stoichiometry for the interaction between
RNA11F7t and desGlaXaS195A by sedimentation equilibrium,
employing a fixed concentration of desGlaXaS195A (1.67 M)
and increasing concentrations of aptamer (0 to 3.2 M, not
shown). Global analysis of multiple data revealed two sedi-
menting species present in reciprocally varying amounts with
increasing RNA11F7t. Molecular weights of these species corre-
sponded to 46,070  390 for unligated desGlaXaS195A and
67,550  580, presumed to represent the aptamer-proteinase
complex. Adequate fits of the sedimentation profiles did not
require the inclusion of a significant amount of free aptamer.
Although these findings are generally consistentwith2mol of
RNA11F7t bound/mol of proteinase in a tight binding interac-
tion, caution is suggested in interpretations. The molecular
weight of the ligated species is heavily dependent on the partial
specific volume of the product of the interaction of
desGlaXaS195A (v  0.721ml/g) with aptamer (v  0.508ml/g),
which in turn was calculated assuming a stoichiometry of 2.
Nevertheless, similar calculations assuming a stoichiometry of
1 yielded a larger molecular weight for the ligated species
(73,700), which is even less consistent with 1 mol of aptamer
bound/mol of desGlaXaS195A at saturation.
Factor Va-dependent Inhibition of Prothrombinase Function—
Evidence implicating a role for aptamer binding to Xa in affect-
ing its interaction with factor Va was pursued by more detailed
kinetic studies of prethrombin 2 cleavage. Initial rates deter-
mined with increasing concentrations of factor Va allow the
indirect assessment of the membrane-dependent interaction
between Xa and Va (21). Velocity curves were systematically
shifted to the right at increasing fixed concentrations of
RNA11F7t, whereas RNAMUT was without effect (Fig. 6). The
data could be adequately described assuming competitive equi-
libria between the binding of aptamer to Xa and the binding of
Xa to Va (Fig. 6). Inferred equilibrium binding parameters for
the interaction of Xa with Va were in agreement with the find-
ings of previous studies (21). Analysis assuming a stoichiometry
of 2 mol of aptamer bound/mol of Xa at saturation yielded an
equilibrium dissociation constant (3 nM) in tolerable agree-
ment with the values determined in direct binding studies. The
FIGURE 5. Sedimentation equilibrium analysis. Absorbance profiles were
measured at 260 nm at sedimentation equilibrium after centrifugation of 1.62
M RNA11F7t in assay buffer lacking polyethylene glycol at 15,000 (‚), 20,000
(Œ), 25,000 (E), and 30,000 (F) rpm at 20 °C. The lines are drawn after global
analysis of scans at 260 and 280 nm with   1.0046 g/ml and v  0.508 ml/g
(48) assuming a homogenous sedimenting species with molecular weight 
12,604  109. Residuals to the fitted lines are shown in the upper panel. The
root mean square deviation for this set was 0.0044.
FIGURE 6. Factor Va dependence of inhibition by RNA11F7t. Initial velocities
for thrombin formation were measured at increasing concentrations of Va in
reaction mixtures containing 1.4 M prethrombin 2, 50 M PCPS, 5 nM Xa, and
concentrations of RNA11F7t fixed at 0 (F), 50 nM (Œ), 200 nM (‚), 1.0 M (), and
2.0 M (ƒ). Initial velocities were also determined using 2.0 M RNAMUT as a
control (E). The lines are drawn after analysis according to competitive equi-
libria with the fitted constants KdXa,Va  1.55  0.3 nM, n  1.19  0.09 mol of
Va/mol of Xa at saturation, KdRNA,Xa  3.14  0.35 nM, n (assumed)  2 mol of
RNA11F7t/mol of Xa at saturation, and rate at saturating Va  83.0  0.9 nM IIa
formed/min.
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findings indicate that binding of RNA11F7t to Xa competes with
the ability of the proteinase to interact with factor Va within
prothrombinase.
Inhibition of Prothrombinase Assembly—Evidence for the
ability of the aptamer to disrupt the assembly of prothrombi-
nase was sought from equilibrium binding studies employing
measurements of the fluorescence anisotropy of OG488-Xa
(21). In the absence of aptamer, increasing concentrations of Va
produced a saturable increase in anisotropy (Fig. 7). This
change reflects the binding of OG488-Xa to factor Va on the
membrane surface (21). Titration curves obtained at increasing
concentrations of RNA11F7t exhibited systematic shifts to the
right, whereas RNAMUThadno effect (Fig. 7). The data could be
adequately described by the system of competitive equilibria
involving mutually exclusive interactions between Va or
RNA11F7t with OG488-Xa (Fig. 7). The fitted terms were con-
sistent with previously established equilibrium parameters for
the interaction between Xa and Va on the membrane surface
(10, 21) as well as parameters for the interaction between
aptamer and Xa established by multiple approaches in this
study (Figs. 4 and 6, Tables 1 and 2). Because prothrombinase
assembles through linked protein-protein and protein-mem-
brane interactions (10), deleterious effects of RNA11F7t on the
binding of Xa to PCPS could also yield apparently competitive
effects on prothrombinase assembly. Right angle light-scatter-
ing measurements of the binding of Xa to PCPS in the absence
andpresence of saturating concentrations of aptamer produced
no evidence for a decrease in affinity for membrane binding by
the Xa-aptamer complex (not shown). Indeed, the greater
amplitude of the light-scattering signal observed in the pres-
ence of saturating concentrations of aptamer and PCPS was
consistent with a larger species bound to membranes in the
presence of RNA11F7t. These findings exclude the potentially
trivial possibility that interference with membrane binding
after the interaction of RNA11F7t with Xa accounts for the abil-
ity of the aptamer to inhibit the assembly of prothrombinase.
Other Functions of X and Xa—Surveys were undertaken to
examine the effects of aptamer binding on other functions of
factors X and Xa. The presence of 250 nM RNA11F7t had a
minor effect on the second order rate constant for the inhibi-
tion of factor Xa by antithrombin III (Table 3). This result is not
out of the ordinary for a ligand that does not occlude access to
the active site of the proteinase. In contrast, 250 nM RNA11F7t
greatly reduced the ability of the truncated two domain form of
TFPI to inhibit Xa (Table 3). Thus, tight binding inhibition of
Xa by this Kunitz inhibitor is mediated by interactions in addi-
tion to those at the active site of the proteinase. At Km concen-
trations of factor X, RNA11F7t had little effect on Xa formation
by the VIIaTFPCPS complex but reduced Xa formation cata-
lyzed by the IXaVIIIa complex (Table 3). Initial velocity studies
over a broader range of aptamer concentrations revealed little
inhibition of Xa formation by the extrinsic Xase at concentrations
as high as1MRNA11F7t, whereas Xa activation by the intrinsic
Xase was reduced by 75% (Fig. 8). Initial velocity studies of Xa
formationby IXaVIIIa at increasing concentrationsof substrate at
different fixed concentrations of aptamer yielded complex curve
shapes consistent with inhibition arising from aptamer binding to
factor X, rendering it a substrate that is cleaved with a reduced
Vmax (not shown). Therefore, binding of RNA11F7t differentially
affects recognition of factor X by the two enzyme complexes
responsible for its activation. Surprisingly, RNA11F7t also inhibited
VIII activationby factorXa (Fig. 8, inset)without affectingcofactor
activation by thrombin (not shown). Thus, features observed for
the inhibition of the Xa-Va interaction are mirrored by effects on
the interaction betweenXa and TFPI as well as the interactions of
X and Xa relevant to intrinsic Xase function.
DISCUSSION
The assembly of proteinase and cofactor into a membrane-
bound enzyme complex profoundly enhances the rate of acti-
vation of the cognate zymogen substrate in several steps of
coagulation (1, 2). These characteristics are exemplified by the
activation of prothrombin by prothrombinase (1, 2). Our find-
ings establish RNA11F7t as a tight binding probe for factor Xa
that competes with factor Va for the assembly of the proteinase
into prothrombinase. Accordingly, the aptamer is effective at
FIGURE 7. Competitive inhibition of prothrombinase assembly. Fluores-
cence anisotropy was measured using 35 nM OG488-Xa, 50 M PCPS, and
increasing concentrations of Va in the presence of fixed concentrations of
RNA11F7t corresponding to 0 (E), 0.35 M (F), 2 M (‚), and 5 M (Œ). The
binding profile in the presence of 5 M RNAMUT () is also illustrated as a
control. The lines are drawn after analysis according to competitive equilibria
using the fitted constants KdXa,Va  0.69  0.2 nM, n  1.08  0.02 mol of
Va/mol of OG488-Xa at saturation, KdRNA,Xa  2.58  1.2 nM, n  2.2  0.39 mol
of RNA11F7t/mol of OG488-Xa at saturation, and rmax  0.058  0.004.
TABLE 3
Effects of RNA11F7t on other functions of factors Xa and X
Measured reactiona Parameter Aptamer RNA11F7tb
Xa  ATIII kobs/I (M1 s1) (1.78  0.17)  103 (1.54  0.04)  103
Xa  TFPI13–161 Ki* (nM) 0.35  0.03 600
X3 Xa (VIIa.TF.PCPS) Rate (nM Xa/min/nM E) 178 203
X3 Xa (IXa.VIIa.PCPS) Rate (nM Xa/min/nM E) 61 17.5
Ki*, overall equilibrium dissociation constant; E, enzyme.
a The indicated reactions and corresponding parameters were determined as described under “Experimental Procedures.”
b Results obtained using RNA11F7t fixed at between 250 and 270 nM.
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inhibiting thrombin formation without affecting access to the
active site of factor Xa, impacting membrane binding or
influencing substrate binding to the enzyme complex. Thus,
RNA11F7t is endowed with properties expected for a specific
inhibitor of the protein-protein interaction between Xa and Va
within prothrombinase.
Difficulties with incisive interference with the assembly of
prothrombinase relate to the high affinity for the membrane-
dependent interaction between Xa and Va (10), the obvious
complexity of macromolecular interactions enjoying resurgent
recognition (52), the contribution of linkage effects in the mul-
ticomponent interactions that stabilize prothrombinase (10) as
well as the likelihood that interfering with a subset in a complex
network of contacts may not yield efficient inhibition of pro-
tein-protein interactions relevant to function. Consequently,
efficient competition for prothrombinase assembly is achieved
by catalytically inactive derivatives of Xa that can participate in
most or all aspects of the interactions of active Xa within pro-
thrombinase (9). Inhibition of the Xa-Va interaction in the
bovine system has also previously been documented with a
monoclonal antibody directed toward the light chain of factor
Va (53). Rather than purely arising from site-specific effects,
inhibition in this case probably also reflects long-range steric
phenomena associated with the binding of an immunoglobulin
probe of roughly comparable size to the cofactor. In line with
such reasoning, modest inhibitory effects, judged by affinity
and/or extent, are observed with peptides presumed to repre-
sent regions that participate in interactions between proteinase
and cofactor (15, 16). Our findings with RNA11F7t are some-
what unexpected in that they illustrate competitive inhibition
of prothrombinase assembly by a relatively small ligand that
binds factor Xa with high affinity in an oligoribonucleotide
sequence-specific interaction.
Analogous approaches have led to the development of inhib-
itory RNA aptamers targeting IXa, VIIa, and thrombin (39, 54,
55). These also bind their target proteinases with high affinity
and interfere with complex macromolecular interactions nec-
essary for function. Highly complementary interactions
between RNA and protein, occluding 1200 Å2 of solvent
accessible surface, have been documented in the x-ray structure
of thrombin bound to its inhibitory RNA aptamer (56). The
ability of an otherwise modestly sized RNA aptamer to inti-
mately engage extensive surfaces on the proteinase in this way
may lie at the heart of the explanation for the repeated success
of these reagents in inhibiting complex but diverse macromo-
lecular interactions.
Mutually exclusive interactions between RNA11F7t and fac-
tor Va for binding to Xa aremost readily interpreted in terms of
the ability of the aptamer to specifically occlude surfaces on the
proteinase that participate in cofactor binding. Although such
straightforward occlusive effects may well contribute to the
inhibitory properties of RNA11F7t, a role for alternative phe-
nomena is implied by the finding that the aptamer binds equiv-
alently to both X and Xa. As the zymogen, factor X, does not
detectably bind factor Va (57), it follows that the binding of
RNA11F7t is probably not confined to structural motifs specific
to the interaction between proteinase and cofactor. We offer
the reasonable speculation that competitive inhibition of the
Xa-Va interaction also reflects indirect or allosteric phenom-
ena wherein RNA11F7t distorts structural features in the pro-
teinase that, in turn, deleteriously impact cofactor binding.
Complexity in the binding of RNA11F7t to Xa is further
implied by the peculiar stoichiometry and the strong Ca2
dependence of the interaction. That the latter property is inde-
pendent of the -carboxyglutamic acid-containing domain
suggests a role for Ca2 ligation at the site in the proteinase
domain and/or in the first epidermal growth factor-like domain
in modulating proteinase structure and impacting RNA11F7t
binding (58, 59). It is equally possible that the findings are unre-
lated to Ca2 binding to either X or Xa but, rather, because of
the stabilization of the inhibitory structure of the aptamer by
bound Ca2.
Despite the fact that RNA11F7t is predominantly monomeric,
all binding and functional studies are consistent with 2 mol of
aptamer bound/mol of X or Xa at equivalent and apparently
non-interacting sites. An alternative explanation is that there
are two equally populated, non-interconverting and differen-
tially folded structures of RNA11F7t, only one of which is capa-
ble of binding Xa. In this case, stoichiometries based on total
RNA11F7t would be overestimated by 2-fold with a correspond-
ing 2-fold overestimate in Kd. This possibility is suggested by
the findings in the filter binding assay wherein 60–65% of
radiolabeled aptamerwasmaximally retained as the bound spe-
cies at saturating concentrations of Xa (not shown). In contrast,
the analytical ultracentrifugation studies are more consistent
with a tight binding stoichiometry of 2. However, the complex-
ity of analyzing such interactions between components with
vastly differing values of v could adversely impact interpreta-
tions. We have been unable to convincingly distinguish
FIGURE 8. Inhibition of X activation. Initial velocities for Xa formation were
determined at increasing concentrations of RNA11F7t for factor X activation
catalyzed by the extrinsic Xase (F) or the intrinsic Xase (E). For measurements
with extrinsic Xase, reaction mixtures contained 0.1 nM VIIa, 43 nM TF/50 M
PCPS, and 100 nM X (Km). For measurements with intrinsic Xase, reaction
mixtures contained 0.2 nM IXa, 10 nM VIIIa, 50 M PCPS, and 40 nM X (Km).
Initial velocities were normalized as v/vo to permit presentation in the same
scale. Note the break in the ordinate between 0 and 0.25. Inset, shown is
analysis of the activation of factor VIII (50 nM) with 3 nM Xa plus 50 M PCPS in
the absence (left panel) or the presence (right panel) of 250 nM RNA11F7t deter-
mined by Western blotting with an anti-A2 antibody. In each panel, lanes 1-9
correspond to reaction times of 0, 20, 40, 60, 90, 120, 180, 300, and 480s.
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between these possibilities either by affinity chromatography
using immobilized Xa or by native gel electrophoresis. These
points highlight the substantial difficulties inherent in the
unambiguous assignment of stoichiometries that deviate signif-
icantly from 1 even when sound physical measurements are
employed.
Finally, it is also possible that the Ca2 dependence of bind-
ing and inhibition is somehow related to the observed stoichi-
ometry of 2. It is possible that binding of RNA11F7t to X and Xa
could facilitate aptamer dimerization in a potentially Ca2-de-
pendent manner. This scenario could explain the inability to
detect a singly ligated Xa species in sedimentation equilibrium
studies or otherwise dissect contributions of the individual
binding events to function. We have also been unable to test
these and other possibilities because of repeated failures in UV-
cross-linking attempts to covalently trap RNA11F7t in complex
with either X or Xa.
The conclusion that RNA11F7t and Va represent mutually
exclusive ligands for factor Xa is based on initial velocity studies
as well as equilibrium binding measurements of prothrombi-
nase assembly. In both cases the datawere adequately described
by competing equilibria in which Xa either binds to Va within
prothrombinase or binds to the aptamer, with agreement
between fitted parameters and directly measured terms for the
individual component interactions. Despite the consistency
betweenmultiple approaches, it remains possible that the bind-
ing interactions are not strictly mutually exclusive. In this case
our data indicate that the affinity of the RNA11F7tXa complex
for Va would be at least 100-fold lower than for Xa alone. There
are no facile approaches to convincingly distinguish this possi-
bility from the alternate case of competitive binding.
In addition to binding Xa and affecting its ability to interact
with Va within prothrombinase, the interaction of RNA11F7t
selectively impacts other functions of factor X and Xa. These
include the effects on the inhibition of Xa by TFPI and the
functions of bothX andXa related to the intrinsic pathway. The
dramatic effect of250 nMRNA11F7t in raising the overall equi-
librium dissociation constant for inhibition by TFPI by 2000-
fold is somewhat unexpected given the high affinity with which
even the truncated inhibitor species binds factor Xa. We have
not investigated this phenomenon in detail, and it remains pos-
sible that the unanticipated effects of the aptamer could con-
tribute to the observations. In contrast, the effects of RNA11F7t
on X activation by the intrinsic Xase and the action of Xa on
VIII are more in line with the effects observed on the assembly
of prothrombinase. In the case of X activation by the IXaVIIIa
complex, aptamer binding to the zymogen transforms it into a
poor substrate, likely with a 5–6-fold lower Vmax, for the
enzyme complex. Coupled with the lack of observable effects of
the aptamer on X activation by the VIIa/TF complex, our find-
ings point to fundamental differences inmechanismunderlying
the recognition of factor X as a substrate by the extrinsic versus
intrinsic Xase complexes. There is some other experimental
support for this idea (22, 60). Inhibition of VIII activation by Xa
further suggests commonalities underlying the interaction of
the proteinase with factor Va as a cofactor or with factor VIII as
substrate. Together, the observations point to differential roles
played bymultiple types of extended surfaces in factorX andXa
in the different biological functions of the zymogen and
proteinase.
A series of DNA and RNA aptamers have been described as
specific inhibitors of the reactions of blood coagulation as well
as the cell adhesive functions of von Willebrand factor with
potential practical utility (39, 54, 55, 61, 62). The use of RNA
aptamers as potential anticoagulants also benefits from the
generalizable strategy developed for the preparation of a spe-
cific antidote that binds the aptamer and obviates its inhibitory
properties (63). Additional considerations arise from the ability
of RNA11F7t to bind both zymogen and proteinase with similar
affinity. This feature along with the Ca2 dependence of its
binding is a likely explanation for the high concentrations
required to prolong clotting times after the incubation of the
aptamer with citrated plasma. Nevertheless, therapeutic
administration of RNA11F7t would lead to its circulation in
blood complexed with the precursor of the proteinase target.
The analogous properties of nematode anticoagulant peptide
C2 and experience with its therapeutic use establish the enzy-
mologic and pharmacokinetic advantages of this feature (64).
On the other hand, whereas some of the other effects of
RNA11F7t on the functions of X and Xa in the intrinsic pathway
could further contribute to its anticoagulant properties,
apparent abrogation of the inhibition of Xa by TFPI suggests
a potential limitation in this regard. It also suggests that
inhibition of coagulation by RNA11F7t arises from the net
effect of the aptamer on multiple steps in the pathways lead-
ing to thrombin formation. Perhaps this is responsible for
the differential response observed in the two coagulation
assay systems (Fig. 1A).
In summary, our studies establish RNA11F7t as a tight binding
ligand for factor Xa with the ability to compete for the interac-
tion between proteinase and its cofactor. This property imbues
the aptamerwith the unique credential of representing a ligand,
generated de novo by SELEX, that can efficiently block the
assembly of the prothrombinase complex. Inhibition of com-
plex assembly is achieved with high affinity despite the fact that
the complex is stabilized by linked protein-protein and protein-
membrane interactions as well as a high affinity interaction
between proteinase and cofactor that likely involves extended
surfaces. We suggest that this property likely reflects a signifi-
cant contribution from more generalized allosteric effects of
RNA11F7t on factor Xa rather than solely resulting from the
direct occlusion of specific interactions between proteinase and
cofactor. Our findings document the feasibility of interfering
with enzyme complex assembly as a viable strategy to specifi-
cally modulate the formation of thrombin as well as other pro-
teinases in the analogous steps of coagulation.
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